KR20220163640A - 단백체의 집단적 정량을 위한 자성 수집을 이용한 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 - Google Patents
단백체의 집단적 정량을 위한 자성 수집을 이용한 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 Download PDFInfo
- Publication number
- KR20220163640A KR20220163640A KR1020210072043A KR20210072043A KR20220163640A KR 20220163640 A KR20220163640 A KR 20220163640A KR 1020210072043 A KR1020210072043 A KR 1020210072043A KR 20210072043 A KR20210072043 A KR 20210072043A KR 20220163640 A KR20220163640 A KR 20220163640A
- Authority
- KR
- South Korea
- Prior art keywords
- module
- magnetic
- tube
- sample
- aptamer
- Prior art date
Links
- 230000005291 magnetic effect Effects 0.000 title claims abstract description 334
- 108091023037 Aptamer Proteins 0.000 title claims abstract description 226
- 238000009739 binding Methods 0.000 title claims abstract description 82
- 230000027455 binding Effects 0.000 title claims abstract description 81
- 108010026552 Proteome Proteins 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 31
- 238000011002 quantification Methods 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 239000011324 bead Substances 0.000 claims description 181
- 239000000523 sample Substances 0.000 claims description 170
- 108090000623 proteins and genes Proteins 0.000 claims description 160
- 102000004169 proteins and genes Human genes 0.000 claims description 152
- 150000007523 nucleic acids Chemical class 0.000 claims description 146
- 102000039446 nucleic acids Human genes 0.000 claims description 145
- 108020004707 nucleic acids Proteins 0.000 claims description 145
- 238000000034 method Methods 0.000 claims description 128
- 238000005406 washing Methods 0.000 claims description 86
- 238000004458 analytical method Methods 0.000 claims description 73
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 67
- 230000033001 locomotion Effects 0.000 claims description 58
- 238000006243 chemical reaction Methods 0.000 claims description 53
- 238000010828 elution Methods 0.000 claims description 46
- 238000012163 sequencing technique Methods 0.000 claims description 44
- 230000008569 process Effects 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 25
- 230000008878 coupling Effects 0.000 claims description 19
- 238000010168 coupling process Methods 0.000 claims description 19
- 238000005859 coupling reaction Methods 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 108091092584 GDNA Proteins 0.000 claims description 14
- 238000004140 cleaning Methods 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 230000003028 elevating effect Effects 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 230000009870 specific binding Effects 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 230000007723 transport mechanism Effects 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 108091027963 non-coding RNA Proteins 0.000 claims description 2
- 102000042567 non-coding RNA Human genes 0.000 claims description 2
- 108020004417 Untranslated RNA Proteins 0.000 claims 1
- 102000039634 Untranslated RNA Human genes 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 70
- 108020004414 DNA Proteins 0.000 description 51
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 47
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 47
- 238000007481 next generation sequencing Methods 0.000 description 43
- 238000005516 engineering process Methods 0.000 description 37
- 238000003752 polymerase chain reaction Methods 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 32
- 239000012472 biological sample Substances 0.000 description 26
- 239000006249 magnetic particle Substances 0.000 description 22
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 21
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 21
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 20
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 19
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 17
- 108091034117 Oligonucleotide Proteins 0.000 description 17
- 201000005202 lung cancer Diseases 0.000 description 17
- 208000020816 lung neoplasm Diseases 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 239000002679 microRNA Substances 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 239000008186 active pharmaceutical agent Substances 0.000 description 11
- 108091070501 miRNA Proteins 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000011534 wash buffer Substances 0.000 description 11
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000006148 magnetic separator Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- -1 poly(vinyl alcohol) Polymers 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000012784 weak cation exchange Methods 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 229920001222 biopolymer Polymers 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012070 whole genome sequencing analysis Methods 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108091032955 Bacterial small RNA Proteins 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 238000010223 real-time analysis Methods 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 102000039471 Small Nuclear RNA Human genes 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000007482 whole exome sequencing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000877 Melamine resin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000005011 phenolic resin Substances 0.000 description 2
- 229920001568 phenolic resin Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000005373 porous glass Substances 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101710116034 Immunity protein Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- OSKIPPQETUTOMW-YHLOVPAPSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2R,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 OSKIPPQETUTOMW-YHLOVPAPSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 229920004896 Triton X-405 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- HCXHLIFQJYSIBK-XVFCMESISA-N [[(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound F[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 HCXHLIFQJYSIBK-XVFCMESISA-N 0.000 description 1
- QPEJOQWVBDJCKB-NNFSRNKVSA-N ac1l8w4m Chemical compound C1([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](C3=CC=4OCOC=4C=C32)NC2=CC=C(C=C2)N=CC=2C3=CC=CC=C3N=C3C4=CC5=C(C(N4CC3=2)=O)COC(=O)[C@]5(O)CC)=CC(OC)=C(O)C(OC)=C1 QPEJOQWVBDJCKB-NNFSRNKVSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000002843 nonmetals Chemical class 0.000 description 1
- NJPPVKZQTLUDBO-UHFFFAOYSA-N novaluron Chemical compound C1=C(Cl)C(OC(F)(F)C(OC(F)(F)F)F)=CC=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F NJPPVKZQTLUDBO-UHFFFAOYSA-N 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 238000001921 nucleic acid quantification Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000035104 rRNA modification Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000001963 scanning near-field photolithography Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002377 thylakoid Anatomy 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
- B03C1/00—Magnetic separation
- B03C1/02—Magnetic separation acting directly on the substance being separated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0663—Stretching or orienting elongated molecules or particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/30—Characterised by physical treatment
- C12Q2523/303—Applying a physical force on a nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/205—Aptamer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2541/00—Reactions characterised by directed evolution
- C12Q2541/10—Reactions characterised by directed evolution the purpose being the selection or design of target specific nucleic acid binding sequences
- C12Q2541/101—Selex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/143—Magnetism, e.g. magnetic label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/149—Particles, e.g. beads
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
도 2는 자동화 액체 처리 장치의 모듈을 사용하여 단백체 결합 압타머의 자기 수집을 수행하는 S610-S620 각각 단계를 예시하는 흐름도이고,
도 3은 분석시료 폐암환자의 혈청에서 준비된 압타머 일차 라이브러리와 비교시료 비폐암환자 혈청에서 준비된 압타머 일차 라이브러리 각각을 구성하는 5,395개의 압타머에 대한 염기서열과 출현빈도의 비율을 비교하여 서로 상이함을 확인한 결과이고,
도 4는 상기 분석시료(10례)와 대조구(21례) 각각에 대해 분석한 결과를 이용하여 분석시료와 비교시료에 대한 db를 구축하였으며 두 그룹을 잘 구분할 수 있는 압타머들을 One-way ANOVA 기법으로 결정한 후, 결정된 압타머의 출현빈도를 4*[(출현빈도-최소)/(최대-최소)]-2로 전환하여 표현한 결과이고,
도 5는 선정된 압타머의 출현빈도로 계층 클러스터링한 결과로 폐암 환자의 혈청과 비폐암 환자의 혈청은 각각 독립된 클러스터를 형성하고 있어, 인간 혈청단백질에 결합하는 압타머 출현빈도로 환자들의 구분할 수 있음을 알 수 있으며,
도 6은 상기 결과와 같이, 생체시료를 구성하는 다중의 단백질, 결합하는 압타머 및 NGS 기술을 이용하여 특정한 생체시료에서 단백질의 프로파일을 탐색 및 분석하여 분석시료인 폐암 환자 혈청단백질에 특이적으로 결합하고 생물학적 의미를 지닌 압타머들을 선정할 수 있다. 이 중에 일련번호 768(압타머에 대해 자체 부여한 번호임) 압타머에 대한, 분석시료인 폐암 환자의 혈청과 비교시료인 비폐암 환자의 혈청에 대한 결합정도를 평가한 결과, 폐암 환자의 혈청에만 특이적으로 반응함을 알 수 있었다.
종류 | Locus | 내 용 | Accession number |
A | At1g65390.1 | defense/immunity protein | GO:0003793 |
B | At5g39310.1 | cell elongation | GO:0009826 |
C | At4g15910.1 | Drought-Induced Protein (Di21) | GO:0009414 |
D | At1g12860.1 | Bhlh Protein | GO:0003677 |
E | At4g02530.1 | Chloroplast Thylakoid Lumen Protein | GO:0009543 |
|
시료 임상정보 | ||||
폐암 | 대조구 | ||||
시료 수 | 10 | 21 | |||
평균 나이 | 64.3 | 56.6 | |||
중앙값 평균 나이 | 65 | 56 | |||
성 | 남자 | 8 | 16 | ||
여자 | 2 | 5 | |||
Histopathology of NSCLC | |||||
Squamous cell carcinoma | 2 | ||||
Adenocarcinoma | 8 | ||||
NSCLC | Stage I | 6 | |||
Stage II | 4 | ||||
Stage III | |||||
Stage IV | |||||
Pneumonia | 21 | ||||
Tuberculosis | 10 | ||||
Benign mass | 2 | ||||
Etc | 17 |
정방향primer | 역방향Primer | 표적유전자 |
TCCTCATGTACTGGTCCCTCAT | GGTGCACTGTAATAATCCAGACTGT | KRAS |
CATACGCAGCCTGTACCCA | GTGGATGCAGAAGGCAGACAG | RET |
TGTCCTCTTCTCCTTCATCGTCT | AGGAGTAGCTGACCGGGAA | RET |
CCATCTCCTCAGCTGAGATGAC | GGACCCTCACCAGGATCTTG | RET |
CCTATTATGACTTGTCACAATGTCACCA | TAGACGGGACTCGAGTGATGATT | BRAF |
CACAGCAGGGTCTTCTCTGTTT | CCTTCTGCATGGTATTCTTTCTCTTCC | EGFR |
TGTCAAGATCACAGATTTTGGGCT | ATGTGTTAAACAATACAGCTAGTGGGAA | EGFR |
GGTGACCCTTGTCTCTGTGTTC | AGGGACCTTACCTTATACACCGT | EGFR |
GGAAACTGAATTCAAAAAGATCAAAGTGCT | GGAAATATACAGCTTGCAAGGACTCT | EGFR |
cttACCAGCTTGTTCATGTCTGGA | AGAGGACTTCGCTGAATTGACC | MET |
GCAGCGCGTTGACTTATTCATG | CACAGCTACTCTCAGAAAGCACT | MET |
AACTGAGCTTGTTGGAATAAGGATGTTAT | CCATTTTGGTTTAATGTATGCTCCACAATC | MET |
CCCATCCAGTGTCTCCAGAAGT | CAAGTGACACTGGTTGTAAATATGCATTT | MET |
GTTATGACAGGATTTGCACACATAGTT | CCCAAGCCATTCAATGGGATCT | MET |
CCCTTCTCTTCACAGATCACGA | CAGACAGATCTGTTGAGTCCATGT | MET |
GCTTGGGCTGCAGACATTTC | GCCAGCTGTTAGAGATTCCTACC | MET |
TGGTCCTGCACCAGTAATATGC | ATTATAAGGCCTGCTGAAAATGACTGA | KRAS |
CCATCCACAAAATGGATCCAGACA | GCTCTGATAGGAAAATGAGATCTACTGTTT | BRAF |
AGGAAATTCCCACTTAGGAACCATTG | AGCAAACTCAGTTGAAATGGTTTGG | MET |
GTTCAGTGTGTCAAACAGTATTCTTGAATG | GTTGGATGAATTTCATAGACAATGGGATC | MET |
ACAAGCATCTTCAGTTACCGTGAA | AAAACTGCAATTCCTCTTGACTATTCTACA | MET |
GCTATGGATGTTGCCAAGCTGT | TAACATGAAAAAGGCTTTGGTTTTCAGG | MET |
GCAACAGCTGAATCTGCAACTC | ATTTTCATTGCCCATTGAGATCATCAC | MET |
CTGTGTTTAAGCCTTTTGAAAAGCCA | CCAAGTACAACAATTGTATTCACATAGCT | MET |
CATAATTAAATGTTACGCAGTGCTAACCA | GCAAACCACAAAAGTATACTCCATGGT | MET |
CAGTCAAACCCTCAGGACAAGA | CCCTCGGTCAGAAATTGGGAAA | MET |
TCTCAGGAATCACTGACATAGGAGAAG | CGAATGAAATTTCGAAGATCTCCATGTTT | MET |
GCTGGTGGTCCTACCATACATG | TTTTTAAAGACTCAGAGCAGGCCTATT | MET |
GAGGCCAGATGAAATACTTCCTTCA | AAAATCAGCAACCTTGACTGTGAATTTT | MET |
TGTCCTTTCTGTAGGCTGGATGA | GGTGGTAAACTTTTGAGTTTGCAGA | MET |
GTGAAGTGGATGGCTTTGGAAAG | AAACTGGAATTGGTGGTGTTGAATTTTT | MET |
CGTCTCCTGGAGATGGATACTCT | CTGTGGAGGAACTTTTCAAGCTG | FGFR1 |
GCAGTTACTGGGCTTGTCCAT | GAGGCGGAGAAGCTCTAACAC | FGFR1 |
GCATGGACAGGTCCAGGTAC | GGAAGACCTGGACCGCATC | FGFR1 |
CCTTACCTGGTTGGAGGTCAA | GGAGACGTCCCTGACCTTACA | FGFR1 |
GAGTTCTTTGCTCCACTTGGGA | CCACACTCTGCACCGCTAG | FGFR1 |
GCACCTTACCTTGTTCAGGCAA | TGGAGTATCCATGGAGATGTGGA | FGFR1 |
AGGAATGCCTTCAAAAAGTTGGGA | TCCAGTGCATCCATGAACTCTG | FGFR1 |
GTGATGGCCGAACCAGAAGAAC | CATGTGCCTCTGCCATTGTTG | FGFR1 |
GAGAGAGGCCTTGGGACTGATA | TCAGAAATGGAGATGATGAAGATGATCG | FGFR1 |
AGCAGGTTGATGATATTCTTATGCTTCC | CCACTCCCTTAGCCTTTATCCTG | FGFR1 |
TTAAACCCAATGCCCAGACCCAAA | CCCTTCTTCTTCCCATAGATGCTCT | FGFR1 |
TCTCCTCTGAAGAGGAGtcatcatc | GGTGTCCGTGTTCATCTGGAAC | FGFR1 |
GGCAGAAAGAGGACTCCTCAGT | CGACTGCCTGTGAAGTGGATG | FGFR1 |
TGTAGATCCGGTCAAATAATGCCTC | GGTTTCATCTGAGAAGCAAGGAGT | FGFR1 |
GCATTAGAGGCCCAGAGAGAGA | TCATCGTCTACAAGATGAAGAGTGGTA | FGFR1 |
GCTGTGGAAGTCACTCTTCTTGG | CTAACACCCTGTTCGCACTGA | FGFR1 |
TTGGAATGGGACAAGATTTTCTTTGC | CGAAAGACTGGTCTTAGGCAAAC | FGFR1 |
AGGACAGAAGCATCACTTACACTTC | CAACTTATGCCACTCTCTGTTTCC | FGFR1 |
AAATGAAAAGCATGTAATCAGGACTTCCTA | ACACTGCGCTGGTTGAAAAATG | FGFR1 |
TGTGGTCAGGTTTGAATTCTTTGC | GCCGTAGCTCCATATTGGACATC | FGFR1 |
CATGCAATTTCTTTTCCATCTTTTCTGG | CTCACAGGTGTTGGGCAGAT | FGFR1 |
CTTTGTCATTTACAAGTACTTTGCAAACAC | TCCCTAAAGCTGGAGTCCCAAATA | ROS1 |
TTCTAGTAATTTGGGAATGCCTGGTT | cgcctcTGAATATTTCTTTAATGTTGTCTT | ROS1 |
GCCTAGGTGCTCCATAATGATGG | AGTCTGGCATAGAAGATTAAAGAATCAAAA | ROS1 |
ACCAATCATGATGCCGGAGAAAG | ACCTGGTGTGGTTGTCAATACC | ALK |
TCACCGAATGAGGGTGATGTTTT | GCAGAGCCCTGAGTACAAGC | ALK |
GGTTGTAGTCGGTCATGATGGT | TGGCCTGTGTAGTGCTTCAAG | ALK |
ccacttcacctagccAGAATTTTTC | CTGACAGGCGATCTTGAACATCA | EML4 |
AGATGATAGTATTTCTGCTGCAAGTACTTC | CACATGATCTTCAGAGATTGCAAGAC | EML4 |
CAAGAAGATGAAATCACTGTGCTAAAGG | CAGCTTCAACTTTCAAAGAAAATATTGCAA | EML4 |
CTCTGTCGGTCCGCTGAAT | GCTGTGTGCGGAAGGAAAAA | EML4 |
GTTCTAGTTCAGTCTTCTTCATTGTACCTT | CGGAAGAAGGTAAACATTAGCTCTACAG | EML4 |
TCTGTTAAGATATGGTTATCGAGGAAAGGA | CAACCATTTCACACAGTCTGTATGG | EML4 |
AGAGAACTCAGCGACACTACCT | TCTGAGCTTTCCACAAGAAATCACTT | EML4 |
GCTTCCAAATAGAAGTACAGGTAAGCT | CTGAGCACATGTCAAGAGCAAATC | EML4 |
TCTTGCCACACATCCCTTCAAA | GCCAGTGTGAGGAGTTTCTGTG | EML4 |
ATGGTATTTCTTTCTTAGAATGTTAGCCCTATC | AAATTTACCTTTATTTCTGCTCCTTTTGCTTT | EML4 |
GAGCATATGCTTACTGTATGGGACT | GCTTTTGCGACTTACGAATAGATAGTTCTA | EML4 |
TTTTTCATTTGTTTAAATGTGTATTGTTCCATG | GGAGAAGGTGATGCTCGAATTTG | EML4 |
gaggaaTCTCATTCTAATGATCAAAGTCCA | CCATTCCCTAGCTCTGTACTTGG | EML4 |
TGTCAGTTACATGTCTTTGATACTCAGAA | GGGTGTTGAAGGTATTTTCGACAATTTAT | EML4 |
CTTGGGAAAATTCAGATGATAGCCGTA | CCAGACATACATAACTGTACATGCAAACAT | EML4 |
CCATAGGGAGACTTTCTCATGTACTC | TAGCATTTAAACATCCCACCACTTCA | EML4 |
CCCTCCTTCCAAATGGACTTAATTTTAAA | TGCACCACTTCCATTGGTTATACAG | EML4 |
CCTCGAGCAGTTATTCCCATGTC | AGACAATTCTGCAATGTTAGTTTTTCCC | EML4 |
aacttttacagtttcttgaggtgattttaatgg | TTTCAATTAGCAAAAATTAAACTAAGAAGGGCA | EML4 |
ACAAAGGTATTCTGTTGTTTCATGTTTCC | CAATGTCTCTAGGTACAGAAGGCAT | EML4 |
GTTCTACTGAAGTTTTCTTCCAAATAGACACT | CTCCAGTTAATAACATCCCATTTCTCATCT | EML4 |
GGCAGTGTGTTCACACTTTGTC | GTGGGACAAAATACCTGAGTTTAGAGTATT | EML4 |
GACTAAAACTTTGAAGTAGTCATTTTTGTCTT | GAATGAACATGGTAATTGGCCGA | EML4 |
TGTCTTGTGTTTCAACAGAAGGAGAATAT | GCTGTCATGGTAGAGAAGGATACG | EML4 |
CCTGAGAAGCTCAAACTGGAGT | cctggccTGATGTTTCCTTTTTAATTTTT | EML4 |
gcacaccagcgttatgacaaag | TGTGTGGATAGAAACTAGATCTCTGGTT | EML4 |
GGTGGTTTGTTCTGGATGCAGA | CAATTGCAGTGAAGTGCTGTGAAT | EML4 |
AGTGGATAGGATTCATTCATTAATTGCCA | TACAGCCAGGAAGGTACCATCT | EML4 |
ATTTCTCTAGTCAACACTGACCTATTTTATTCT | TCCCAATAATTTTACAACTTGTTCTACTTCACT | EML4 |
GTAGCAGTAATTGAATTGATACTTGAAGGAGA | CGCTCCAGGTCCAGAAGAAAATATG | EML4 |
GCAAATACCATAATTACATGCGGTAAATCT | GCCATGACAACTTGATGCTTATTAAACAAT | EML4 |
TTTTTAAATGGCATTAGTTCTGTGTGCT | GCTCAAAAGTGCCAAGTCCAATA | EML4 |
TCTGTTACTCTATCCACACTGCAGAT | ACTTCATGGCCACATAAACACAAAAC | EML4 |
AACAGTATTGGCTAGCTGTTGAACT | ATACTTACAGTACAATATTTCATAGTCTCCCGA | EML4 |
CCCAGACAACAAGTATATAATGTCTAACTC | CCCTGACAGACACATCTTAGCatatatata | EML4 |
CAAGCACTATGATTATACTTCCTGTTTCT | ACAAACCACTTCTTTACATCAGGTGT | EML4 |
TTAATAAGCATCAAGTTGTCATGGCAAAAA | GGCTCTACAGTAGTTTTGCTCCATA | EML4 |
AGACTCAGGTGGAGTCATGCTTA | CCTGGTCTAAGAGATGGGACTGA | EML4 |
ATTTCTGAAACAGGCATGTCAAGAATG | CCAGTTGATATCAGGTGACTGTCATTG | EML4 |
AGCCATGTCACCAATGTCAGTTTTA | GGCTTTGGTTAGAGTAGTATCCGCTA | EML4 |
AGTTATCTTTGCCTCAGAATGAGACTG | GTGGGAGAACTGCTTATTCTACTTTCC | EML4 |
GCCCTTAAATGAGACAGCTGAAGA | GCTTATCTCGTTGCATGGCTCTT | EML4 |
GAGACCTTGGTGAGCCTCTTTATG | ACATGCAGCTGAAGGAAAAGAGTT | EML4 |
CAGCTATAAATGCAGGCTTCGAGTA | GTTCCTCGTAAAATAAAGTTTCGTGATGT | EML4 |
GGAAAGGCAGATCAATTTTTAGTAGGC | ACCCTGAAAATGAAAGACACTCATTGTTAT | EML4 |
GCTAATTTTTCTGCATCCCTGTGTT | GGGATACTGAAACAGATGGACTTTACAAA | EML4 |
GTGATAGCTGTTGCCGATGACT | GAGTATCATGGAGAGGAATCAGTAACCTAT | EML4 |
CTTTTGATGACATTGCATACATTCGAAAGA | CAGTTATCTTTTCAGTTCAATGCATGCT | PIK3CA |
ATCCGCAAATGACTTGCTATTATTGATG | CCCAGGATTCTTACAGAAAACAAGTG | NRAS |
GGGTGAGGCAGTCTTTACTCAC | GCCGTTGTACACTCATCTTCCTAG | ALK |
CCTCACCTCTATGGTGGGATCA | GCTCGCCAATTAACCCTGATTACT | NRAS |
CAGGTCTCTCCGGAGCAAA | GCCAAGTCCCTGTGTACGA | HER2 |
AGAACCTCTCAACATTGTCAGTTTTCT | GCTCTGAGTAGAACCATTGCTCA | MET |
TTGGCACAACAACTGCAGCAAA | CCAGAACATTGTTCGCTGCATTG | ALK |
GTCTCTCGGAGGAAGGACTTGA | CAGACTCAGCTCAGTTAATTTTGGTTAC | ALK |
CAGCTGGTGACACAGCTTATG | CTCCGGAGAGACCTGCAAAGAG | HER2 |
TATGCAGATTGCCAAGGTATGCA | AATGGGAAGCACCCATGTAGAC | HER2 |
GGGTGTCTCTCTGTGGCTTTAC | ACTCTGTAGGCTGCAGTTCTCA | ALK |
GCCAATGAAGGTGCCATCATTC | CTCAGGCATCCCAGGCACAT | AKT1 |
ATTTTACAGAGTAACAGACTAGCTAGAGACA | AAAGAAAAAGAAACAGAGAATCTCCATTTTAGC | PIK3CA |
GAAATTTAACAGGGTGTTGTTGTGCA | CTGTTCATCTGACAGCTGGGAAT | DDR2 |
GCTGGAGGAGCTAGAGCTTGAT | GCTTGTGGGAGACCTTGAACAC | MEK1 |
TGGGTGGTCAGCTGCAAC | CATGCTTCAATTAAAGACACACCTTCTTTAA | ALK |
GCTCTGAACCTTTCCATCATACTTAGAAAT | ccagactaacaTGACTCTGCCCTATATAAT | ALK |
AAAGAAGGTGTGTCTTTAATTGAAGCAT | gggtctaatcccatctccagtct | ALK |
TCAtgttagtctggttcctccaaga | gggttatacttgcaacacagtct | ALK |
agggaaggctgggtgaacc | actgactttggctccagaacc | ALK |
ggagcctaaggaagtttcagcaag | cactgctgtgattgcactgaag | ALK |
ggttctggagccaaagtcagtc | aactataggaaacacaactgaccaagatc | ALK |
caatcacagcagtggatttgagg | aggcggaattagagcacagatc | ALK |
GAAGAGCCACATCAtgaaaagatctct | agttaccatccctgcctacaga | ALK |
ggacctctttggactgcagttt | ggtagagctctttaggatttttcaaaacca | ALK |
ggttgtcaatgaaatgaattcaccaacata | ACAGAATCTACCCACTGAATCACAATTT | ALK |
AAACTCCATGGAAGCCAGAACA | ttcattcgatcctcaggtaacccta | ALK |
tggaccgaccgtgatcagat | ATCTGCCGGTAGAAGGGAGAT | ALK |
CCTTTGAGGGATGGCACCATAT | GAGACATGCCCAGGACAGATG | ALK |
CCTTTCCCTCTGCCCTTTTCAA | AGAGAGATAGGAAAATCGGTTTCTGAGTAT | ALK |
GGCTCACAGGCTGAACAGAAAT | ACTTCTAGCTCCCACATGCTTC | ALK |
CATTACATAGGGTGGGAGCCAAA | TGTGTATCCTCCTGGCTGATCA | ALK |
GCTTTCACCATCGTGATGGACA | AAACGGAAGCTCCCAACCTT | ALK |
CTGATCAGCCAGGAGGATACAC | CCAAGGTGTCACTTCGTTATGC | ALK |
CCCACCCAATTCCAGGGACTA | GGCTTTCTCCGGCATCATGAT | ALK |
TGCTTTTCTAACTCTCTTTGACTGCA | GATTGTGGCACAGAGATTCTGATACTT | MET |
CACAGCCTGAGACACTATTCAGTC | ACTCTCGCTGATCCTCTCTGT | ALK |
ATGTATTTAACCATGCAGATCCTCAGTTT | ATCTTGTTCTGTTTGTGGAAGAACTCT | PTEN |
GGATGAGCTACCTGGAGGATGT | CCATCTGCATGGTACTCTGTCT | HER2 |
TCTTTGTCTTCGTTTATAAGCACTGTCA | GTGTTCTTGCATAAAAACACTTCAAATG | ROS1 |
TGAAACTTGTTTCTGGTATCCAAAAATCAT | CTGGCTTGCAAAAATCCAGTAGTAG | ROS1 |
TTCCTTTAGGAAATGTTAACAGTGCATTTG | GATTAAAAATGGTGTAGTATGATTTGTGTACTT | ROS1 |
ACTTACCAAAGGTCAGTGGGATTG | CTCTGTGTGCTTAGGTAGAGCTG | ROS1 |
CTGTGACCACACCTGTCATGTA | AAGAAGGCAAGACCCTTAAAGGAG | RET |
AGCTCTACCTAAGCACACAGAGTAATA | GTGGTTTGTTgctctctgcaaaaa | ROS1 |
GGCCCAATGTGTGGATAGAAC | CAGGACAACTTCTCTACATAGCCA | RET |
GTGTGGATAGAACTTTGGTGGGA | GAAGTGTCCAGGACAACTTCTCT | RET |
GGGTGGCTATGTAGAGAAGTTGT | CTACATGACAGGTGTGGTCACA | RET |
CGAAGTACTGAGTCCAAGCCAT | GACAAGTTCCAATGTGCAGAGAAC | RET |
CTTCTGCACTGAAATCTTTCTACAGAATATATT | gaatctagataccttgccggtgaag | ROS1 |
cgactagaagcaactccgttca | gctcactgctcttccttctctct | ROS1 |
tagattcgctcatcaaaattgactagaagg | gcacagttctttggaaaagcaatttc | ROS1 |
gggaaattgcttttccaaagaactg | cccagggagttcagtaagcttag | ROS1 |
atcaaaagcaaggtgtttttgcttt | ATAATGCCAACTATTTAGTATCCAAAGACTGAG | ROS1 |
AAAAACTAATTAAATCCAGGTAAAAAGCCAT | TCGTTTATGGGTGATTTTGACAAATAAGTTTT | ROS1 |
GCCATATATAAGTACACAAATCATACTACACCA | GTTTGTTTTGGTTTATTTTGACTCGTTTATGG | ROS1 |
TCACCCATAAACGAGTCAAAATAAACCA | CAATGATAAACACTCTTGTACTCTGCaaaa | ROS1 |
CTGCACATTGGAACTTGTCCATG | TTCTCCTAGAGTTTTTCCAAGAACCAAG | RET |
GTGGGAATTCCCTCGGAAGAA | TGCCTGGCAGGTACCTTTC | RET |
AGTCACTGTCCCTGTGACCAT | ACGTAGGGCTATATAATACCAGAAAACTCA | RET |
GCATAGGGACACGTTTCTGTCAT | AGGCTGTGCTCATTACACCAG | RET |
CATTTGGAACAGAGGAAAATTTTGACCTC | AGaccactattgccctcttacaga | RET |
CCAGTGCCAGCTGGTGTAA | GTGGGAAGGCCTGAGAACAC | RET |
GGGCAGTAAATGGCAGTACC | TCGGCACCACTGGGTACAG | RET |
TCACATCCAGGTTATATTCCTCAGTAGAAA | gtaagcttcgttccaatactttttctacat | ROS1 |
TTTAGGACCAAGAAATCTCAGTCTTTGG | GTTTCCTCTACACAACTGAAACTACCT | ROS1 |
CTCAGTCTTTGGATACTAAATAGTTGGCA | tcctcatgccatagtttgccag | ROS1 |
GTCCCAACCATGTCAAAATTACAGAC | CCATGGGCTAGACACCACT | HER2 |
atttgctcttccatgacaggctta | caagtatctcctgatggatgaatgga | BIM |
ccagtgtgtgtatatcacatacttcattta | agcaattccacttccaagtatatatccaaaaa | BIM |
AAAGTTAATGTACCGAGGTAAGTTTTCAGT | CTGTAGAATGTCCAGAGAAAATTATGGACT | BIM |
GAAAGGACTTAGCCAGATGTGAGTTT | CAAAGTCAAGAGAACCACTTATCAACTCA | BIM |
GTCTTAGTTCATGCCTGAAGACCA | TGACTTCTTTGTGGAAAATGTATTTTGCAA | BIM |
ATTCTTTACTCAACCCTATCCATGAAGTTC | CTGGCTAAGGCGAACCTCTTTAT | BIM |
CATTTCTAAATACCATCCAGCTCTGTCT | CATGTGTAGCTGCTGGGATG | BIM |
GCACACCTGTGAGGTGGTG | CTGAAATGAGTTCACGAGCAGTAGTA | BIM |
GGGCTGGAAGTTTTATTATTGCTGT | CCTGTTAACTCATTTAGTAAGCAAGGATGT | BIM |
GTTAACGTCTTCCTTCTCTCTCTGT | TGAGGTTCAGAGCCATGGAC | EGFR |
CATGCGAAGCCACACTGACGT | CTTTGTGTTCCCGGACATAGTCCA | EGFR |
TCATCACGCAGCTCATGCCCTT | GTGAGGATCCTGGCTCCTTATCTC | EGFR |
gctggtACTTTGAGCCTTCACAG | CACCAGCCATCACGTATGCTTC | HER2 |
TCTCCCATACCCTCTCAGCGTA | CAGCCATAGGGCATAAGCTGTG | HER2 |
210: 자성 모듈 220: 커버 모듈
300: 딥-웰 플레이트 301: 1차 결합용 웰
302: 1차 세척용 웰 303: 2차 결합용 웰
304: 2차 세척용 웰 305: 용출용 웰
400: 이동부 410: 제1 이동 모듈
420: 제2 이동 모듈
Claims (18)
- 분석 대상 시료에, 그 시료에 존재하는 단백체의 집단적 정량을 하기 위해서,
(a) 분석 대상 시료에, 그 시료에 존재하는 단백체와 Magnetic Beads(자성비드)를 접촉시켜 제조된 단백체-자성비드 복합체를 미결합 단백체를 포함한 상기 분석대상 시료를 구성하는 혼합물로부터 세척 및 분리를 자기력으로 실시하는 단백체-자성비드 복합체의 1차 자기 수집 단계;
(b) 상기 1차 수집된 복합체와 압타머 풀을 접촉시킴으로써, 제조된 압타머 풀-단백체-자성비드 복합체를 미결합하거나 비특이적으로 결합한 압타머들로부터 세척 및 분리를 자기력으로 실시하는 압타머 풀-단백체-자성비드 복합체의 2차 자기 수집 단계; 및
(c) 상기 2차 수집된 복합체에 포함된 결합 압타머 풀을 용출하는 단계를 포함하는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 - 제1항에 있어서, 상기 Magnetic Beads는
(a) 친화성 리간드(affinity ligand);
(b) 친수성 리간드(hydrophilic ligand);
(c) 소수성 리간드(hydrophobic ligand); 및
(d) 이온 교환기(ion-exchange groups)를 포함하는 군에서 선택되어진 어느 하나가 고정된 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비
청구항 2
제1항 내지 제2항에 있어서, 상기 Magnetic Beads는 MB-C3, C8 및 C18, MB-WCX, WAX, MB-IMAC Fe Cu ?? MB-IAC Prot G를 포함하는 군에서 선택되어진 어느 하나를 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 - 제1항에 있어서, 상기 압타머 풀은
(a) 무작위 서열을 가져 다양한 단백질들에 대한 잠재적 결합 능력을 가진 압타머 풀;
(b) (i) 무작위 서열을 가져 다양한 단백질들에 대한 잠재적 결합 능력을 가진 압타머 풀을 제작하고, (ii) 이 압타머 풀을 상기 (a) 단계에서와 동일한 분석 대상 시료의 표적 단백질 집단과 반응시켜 각 압타머와 각 표적 단백질 사이에 특이적 결합을 유도하여 복합체 집단을 형성시키고, (iii) 비결합한 압타머를 제외시켜 그 복합체 집단을 분리하고, (iv) 그 복합체 집단의 압타머를 증폭하여 얻어진 압타머 풀; 및
(c) 하나 이상의 단백질들에 대한 결합 능력을 가진 압타머 풀을 포함하는 군에서 선택되어진 어느 하나 이상을 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 - 제1항 및 제3항에 있어서, 상기 압타머는 PCR의 프라이머 세트가 상보적으로 결합할 수 있는 부위 또는 상기 상보적인 결합을 연결될 수 있는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비
- 제1항에 있어서, 상기 제조한 압타머-단백체-비드 복합체로부터 결합 압타머를 용출하는 단계는 온도, pH 및 염으로 이루어진 군에서 선택되어진 어느 하나 이상을 사용하는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비
- 제1항에 있어서, 상기 집단적 정량은 PCR, 혼성화 및 염기서열 결정을 포함하는 군에서 선택되어진 어느 하나 이상을 사용하는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비
- 분석 대상 시료 중의 표적 단백체와 표적 유전체를 동시분석하기 위해서,
(a) (i) 분석 대상 시료에, 그 시료에 존재하는 단백체와 Magnetic Beads(자성 비드)를 접촉시켜 제조된 단백체-자성 비드 복합체를 미결합 단백체를 포함한 상기 분석대상 시료를 구성하는 혼합물로부터 세척 및 분리를 자기력으로 1차 자기 수집하고, 상기 자기 수집된 복합체에 압타머 풀을 처리하여, 형성된 압타머 풀-단백체-자성비드 복합체를 미결합하거나 비특이적 결합한 압타머들로부터 세척 및 분리를 자기력으로 2차 자기 수집한 복합체에서 결합 압타머 풀을 용출하는 단계; 및 (ii) 상기 분석 대상 시료와 동일한 분석 대상 시료에서 자성비드를 접촉시켜 제조된 표적 핵산이 포함된 핵산-자성비드 복합체에서 표적핵산을 포함된 핵산을 용출하는 단계; 및
(b) 상기 용출된 압타머 풀과 상기 용출되고 표적 핵산이 포함된 핵산을 혼합하는 단계; 를 포함하는 것을 특징으로 하는 방법. - 제7항에 있어서,
상기 표적 핵산은 gDNA, RNA 또는 이들의 혼합물인 것을 특징으로 하는 방법. - 제7항에 있어서,
상기 gDNA는 서열 결실, 서열 삽입, 단일염기다형성(SNP) 및 메틸화 시토신 중 하나 이상을 가진 gDNA인 것을 특징으로 하는 방법. - 제7항에 있어서,
상기 RNA는 mRNA, pre-mRNA, ncRNA(noncoding RNA) 또는 이들의 혼합물인 것을 특징으로 하는 방법. - 자성모듈(210) 및 커버모듈(220)을 포함하는 자성부(200);
1차 결합용 웰(301), 1차 세척용 웰 (302), 2차 결합용 웰(303), 2차 세척용 웰(304) 및 용출용 웰(305) 등의 딥-웰을 포함하는 딥-웰 프레이트(300); 및
제1이동 모듈(410) 및 제2 이동 모듈(420)을 포함하는 이동부(400);를 포함하는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 자동화 장비(100) - 제11항에 있어서, 다음의 단계를 포함하는 제1 이동 모듈 및 제2 이동 모듈을 갖는 장치에서 자성 비드를 이송하기 위한 자성 모듈 및 반응용액 혼합을 위한 커버 모듈을 사용하여 분석 대상 시료, 그 시료에 있는 단백체에 특이적으로 결합하는 압타머 풀의 제조 자동화 장비로,
(a) 상기 제1 이동 모듈 및 상기 제2 이동 모듈을 상기 자성 모듈 및 상기 커버 모듈과 각각 체결하는 단계;
(b) 상기 자성 모듈 및 상기 커버 모듈을 1차 결합용 웰의 상부 공간으로 이동시키는 단계;
(c) 상기 커버 모듈을 하강시켜서 상기 1차 결합용 웰의 내부 공간으로 상기 튜브를 위치시키는 단계;
(d) 상기 커버 모듈은 1차 결합용 웰 내 분석대상 시료에 있는 단백체 및 자성비드 반응용액을 혼합하여 자성비드 복합체를 제조 하는 단계;
(e) 상기 자성 모듈을 하강시켜 상기 로드를 튜브에 삽입시켜 1차 결합용 웰 내 자성비드 복합체와 접촉하는 단계;
(f) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 세척용액이 있는 1차 세척용 웰로 이동시켜 상기 자성비드 복합체를 자기 수집하고 세척하는 단계;
(g) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 자성비드 복합체를 압타머 풀 반응용액이 있는 2차 결합용 웰로 이동시켜 압타머 풀-단백체-자석비드 복합체를 제조하는 단계;
(h) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 세척용액이 있는 1차 세척용 웰로 이동시켜 상기 자성비드 복합체를 2차 자기 수집하고 세척하는 단계; 및
(i) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 용출용액이 있는 용출용 웰로 압타머 풀의 용출을 하는 단계.
여기서, 상기 자성 모듈은 자성 비드를 수집하기 위한 자기력-발생 물질을 포함하는 로드; 상기 로드가 연결된 로드-지지부; 및 상기 로드-지지부 상의 제1 체결부로서, 상기 로드-지지부를 상기 제1 이동 모듈과 체결하도록 구성되는 제1 체결부를 포함하고; 및
상기 커버 모듈은 튜브로서, 상기 튜브가 단백체와 자성비드 혼합용액을 혼합하고 상기 로드가 상기 튜브에 삽입되고 상기 삽입된 로드가 상하 방향으로 상기 튜브에서 이동할 때, 상기 로드를 가이드하는 튜브; 상기 튜브에 연결된 튜브-지지부; 및
상기 튜브-지지부 상의 제2 체결부로서, 상기 튜브-지지부를 상기 제2 이동 모듈과 체결하도록 구성되는 제2 체결부를 포함하고; 상기 자성 모듈의 상기 로드는 상기 커버 모듈의 상기 튜브에 삽입가능하며, 상기 제1 이동 모듈 및 상기 제2 이동 모듈 중 최소한 하나는 상-하, 좌-우 및 전-후 방향으로 이동 가능한 것을 특징으로 한다. - 제11항 내지 제12항에 있어서, 상기 웰은 샘플, 용해 시약, 및 자성 비드를 포함하는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 자동화 장비.
- 제11항 내지 제12항에 있어서, 상기 장치는 자동화 액체 처리 장치인 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 자동화 장비.
- 제11항 내지 제12항에 있어서, 상기 제1 이동 모듈 및 상기 제2 이동 모듈을 상기 자성 모듈 및 상기 커버 모듈과 각각 체결하는 단계를 제외한 단계들은 세척 과정 또는 용출 과정에 대하여 추가적으로 실시되는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 자동화 장비.
- 제15항에 있어서, 상기 제1 이동 모듈 및 상기 제2 이동 모듈 중 최소한 하나는 수송 메커니즘 및 다중-기능 프로브를 포함하는 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 자동화 장비.
- 제15항에 있어서, 상기 제1 이동 모듈 및 상기 제2 이동 모듈 중 최소한 하나는 파이펫터 모듈 또는 그립퍼 모듈인 것을 특징으로 하는 단백체 결합 압타머 풀의 제조 자동화 장비.
- 제11항에 있어서, 다음의 단계를 포함하는 제1 이동 모듈 및 제2 이동 모듈을 갖는 장치에서 자성 비드를 이송하기 위한 자성 모듈 및 반응용액 혼합을 위한 커버 모듈을 사용하여 분석 대상 시료, 그 시료에 있는 단백체에 특이적으로 결합하는 압타머 풀 및 유전체의 제조 자동화 장비로,
단백체 결합 압타머 풀의 제조는
(a) 상기 제1 이동 모듈 및 상기 제2 이동 모듈을 상기 자성 모듈 및 상기 커버 모듈과 각각 체결하는 단계;
(b) 상기 자성 모듈 및 상기 커버 모듈을 1차 결합용 웰의 상부 공간으로 이동시키는 단계;
(c) 상기 커버 모듈을 하강시켜서 상기 1차 결합용 웰의 내부 공간으로 상기 튜브를 위치시키는 단계;
(d) 상기 커버 모듈은 1차 결합용 웰 내 분석대상 시료에 있는 단백체 및 자성비드 반응용액을 혼합하여 자성비드 복합체를 제조 하는 단계;
(e) 상기 자성 모듈을 하강시켜 상기 로드를 튜브에 삽입시켜 1차 결합용 웰 내 자성비드 복합체와 접촉하는 단계;
(f) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 세척용액이 있는 1차 세척용 웰로 이동시켜 상기 자성비드 복합체를 자기 수집하고 세척하는 단계;
(g) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 자성비드 복합체를 압타머 풀 반응용액이 있는 2차 결합용 웰로 이동시켜 압타머 풀-단백체-자석비드 복합체를 제조하는 단계;
(h) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 세척용액이 있는 1차 세척용 웰로 이동시켜 상기 자성비드 복합체를 2차 자기 수집하고 세척하는 단계; 및
(i) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 용출용액이 있는 용출용 웰로 압타머 풀의 용출을 하는 단계; 및
유전체의 제조는
(a) 상기 자성 모듈 및 상기 커버 모듈을 핵산 1차 결합용 웰의 상부 공간으로 이동시키는 단계;
(b) 상기 커버 모듈을 하강시켜서 상기 핵산 1차 결합용 웰의 내부 공간으로 상기 튜브를 위치시키는 단계;
(c) 상기 커버 모듈은 핵산 1차 결합용 웰 내 분석대상 시료에 있는 핵산 및 자성비드 반응용액을 혼합하여 자성비드 복합체를 제조 하는 단계;
(d) 상기 자성 모듈을 하강시켜 상기 로드를 튜브에 삽입시켜 핵산 1차 결합용 웰 내 자성비드 복합체와 접촉하는 단계;
(e) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 세척용액이 있는 핵산 1차 세척용 웰로 이동시켜 상기 자성비드 복합체를 자기 수집하고 세척하는 단계; 및
(f) 상기 자성 모듈 및 상기 커버 모듈을 상승시켜서 용출용액이 있는 핵산 용출용 웰로 압타머 풀의 용출을 하는 단계.
여기서, 상기 (i) 단계와 상기 (f)의 용출단계에서 얻은 용액을 단백체 및 유전체 분석에 사용한다.
또한, 상기 자성 모듈은 자성 비드를 수집하기 위한 자기력-발생 물질을 포함하는 로드; 상기 로드가 연결된 로드-지지부; 및 상기 로드-지지부 상의 제1 체결부로서, 상기 로드-지지부를 상기 제1 이동 모듈과 체결하도록 구성되는 제1 체결부를 포함하고; 및
상기 커버 모듈은 튜브로서, 상기 튜브가 단백체와 자성비드 혼합용액을 혼합하고 상기 로드가 상기 튜브에 삽입되고 상기 삽입된 로드가 상하 방향으로 상기 튜브에서 이동할 때, 상기 로드를 가이드하는 튜브; 상기 튜브에 연결된 튜브-지지부; 및
상기 튜브-지지부 상의 제2 체결부로서, 상기 튜브-지지부를 상기 제2 이동 모듈과 체결하도록 구성되는 제2 체결부를 포함하고; 상기 자성 모듈의 상기 로드는 상기 커버 모듈의 상기 튜브에 삽입가능하며, 상기 제1 이동 모듈 및 상기 제2 이동 모듈 중 최소한 하나는 상-하, 좌-우 및 전-후 방향으로 이동 가능한 것을 특징으로 한다.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210072043A KR20220163640A (ko) | 2021-06-03 | 2021-06-03 | 단백체의 집단적 정량을 위한 자성 수집을 이용한 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210072043A KR20220163640A (ko) | 2021-06-03 | 2021-06-03 | 단백체의 집단적 정량을 위한 자성 수집을 이용한 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220163640A true KR20220163640A (ko) | 2022-12-12 |
Family
ID=84391460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210072043A KR20220163640A (ko) | 2021-06-03 | 2021-06-03 | 단백체의 집단적 정량을 위한 자성 수집을 이용한 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20220163640A (ko) |
-
2021
- 2021-06-03 KR KR1020210072043A patent/KR20220163640A/ko not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104350152B (zh) | 选择性核酸片段回收 | |
US8110351B2 (en) | Method for isolating nucleic acids and protein from a single sample | |
JP2018046856A (ja) | 細胞中の複数のエピトープを同定するためのダイナミックレンジを高めること | |
KR102512168B1 (ko) | 차세대서열결정법을 이용한 표적 단백질의 집단적 정량 방법과 그 용도 | |
JP2018509178A (ja) | 核酸の高度並列型および正確な測定方法 | |
Yüce et al. | Systematic evolution of ligands by exponential enrichment for aptamer selection | |
US11667957B2 (en) | Methods and compositions for identifying ligands on arrays using indexes and barcodes | |
KR20180041331A (ko) | 분자결합핵산 선정과 표적분자 동정 방법 및 키드, 그리고 그들의 용도 | |
Xu et al. | Microfluidic single‐cell multiomics analysis | |
EP4281586A2 (en) | Emulsification with magnetic hydrogels | |
CN116710571A (zh) | 用于下一代测序文库制备的电泳装置和方法 | |
WO2018134907A1 (ja) | 同一細胞複数生体分子抽出装置および方法 | |
KR20220163640A (ko) | 단백체의 집단적 정량을 위한 자성 수집을 이용한 단백체 결합 압타머 풀의 제조 및 이의 자동화 장비 | |
KR20220164163A (ko) | 단백체의 프로파일 또는 단백질의 정량을 위한 자기 수집을 이용한 압타머 풀의 제조 및 이의 자동화 장비 | |
KR102403628B1 (ko) | 시료의 표적분자 집단에 대한 프로파일을 얻는 방법 | |
EP1649060B1 (en) | Mrna expression analysis | |
CN112858693A (zh) | 一种生物分子检测方法 | |
US20240191299A1 (en) | Chemical sample indexing for high-throughput single-cell analysis | |
CN118186591B (zh) | 一种高效的单细胞空间位置和遗传信息共分析的建库方法及其应用 | |
WO2024006712A1 (en) | Methods for preparation and analysis of proximity-ligated nucleic acids from single cells | |
WO2022008649A1 (en) | Spatial analysis of multiple targets in tissue samples | |
KR20220077546A (ko) | 시료의 표적분자 집단에 대한 프로파일을 얻는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20210603 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230518 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20230925 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230518 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |